Company intelligence / Profile preview

Burst Biologics

Boise, Idaho, United Statesfda.gov ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

The company has faced FDA regulatory issues. In 2022, the FDA issued a warning letter stating that their products (BioBurst Fluid and BioBurst Rejuv) were unapproved drugs and biological products, contrary to the company's claim that they were 361 registered tissues.

Therapeutic areas: Rheumatology
Modalities: Biologics derived from human umbilical cord blood
Industry: Biotech

Drug pipeline

1 asset

BioBurst Fluid

Preclinical

Beyond the preview

Go deeper on Burst Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burst Biologics.

Explore the full profile